Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Beuzard

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Nature Medicine|March 25, 2014
An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemiaMichael Dussiot, Thiago T Maciel, Aurélie Fricot, et al.
Current Gene Therapy|November 28, 2014
Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell diseaseOlivier Negre, Cynthia Bartholomae, Yves Beuzard, et al.
Nature|August 27, 2014
HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemiaJean-Benoît Arlet, Jean-Antoine Ribeil, Flavia Guillem, et al.
The New England Journal of Medicine|March 2, 2017
Gene Therapy in a Patient with Sickle Cell DiseaseJean-Antoine Ribeil, Salima Hacein-Bey-Abina, Emmanuel Payen, et al.
Nature|September 17, 2010
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaMarina Cavazzana-Calvo, Emmanuel Payen, Olivier Negre, et al.
Nature Medicine|January 25, 2022
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trialElisa Magrin, Michaela Semeraro, Nicolas Hebert, et al.
The New England Journal of Medicine|April 19, 2018
Gene Therapy in Patients with Transfusion-Dependent β-ThalassemiaAlexis A Thompson, Mark C Walters, Janet Kwiatkowski, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Nature Medicine|March 25, 2014
An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemiaMichael Dussiot, Thiago T Maciel, Aurélie Fricot, et al.
Current Gene Therapy|November 28, 2014
Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell diseaseOlivier Negre, Cynthia Bartholomae, Yves Beuzard, et al.
Nature|August 27, 2014
HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemiaJean-Benoît Arlet, Jean-Antoine Ribeil, Flavia Guillem, et al.
The New England Journal of Medicine|March 2, 2017
Gene Therapy in a Patient with Sickle Cell DiseaseJean-Antoine Ribeil, Salima Hacein-Bey-Abina, Emmanuel Payen, et al.
Nature|September 17, 2010
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaMarina Cavazzana-Calvo, Emmanuel Payen, Olivier Negre, et al.
Nature Medicine|January 25, 2022
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trialElisa Magrin, Michaela Semeraro, Nicolas Hebert, et al.
The New England Journal of Medicine|April 19, 2018
Gene Therapy in Patients with Transfusion-Dependent β-ThalassemiaAlexis A Thompson, Mark C Walters, Janet Kwiatkowski, et al.
Pageof 3